WellPoint Plans CER Guidance, Building On Progress With Outcomes Data

WellPoint believes its discussions with drug manufacturers about patient outcomes have improved in the 18 months since it published technology assessment criteria focusing on that topic. Now it is updating its criteria to include how to submit results from comparative effectiveness research

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet